NasdaqGS:IMCRBiotechs
Immunocore (IMCR) Returns To Quarterly Profit And Tests Bearish Profitability Narratives
Immunocore Holdings (IMCR) opened 2026 with Q1 revenue of US$106.7 million and basic EPS of US$0.26, against a trailing twelve month revenue base of US$412.8 million and a basic EPS loss of US$0.55. Over recent quarters the company has reported revenue of US$84.1 million in Q4 2024, US$93.9 million in Q1 2025, US$98.0 million in Q2 2025, US$103.7 million in Q3 2025, US$104.5 million in Q4 2025 and US$106.7 million in Q1 2026. Over the same period, basic EPS has ranged from a loss of US$0.47...